Premarket Notification 510(k) (New Device)

MAY 13 2008

AngioDynamics, Inc. DuraMaxTM Hemodialysis Catheter and Procedure Kit

General Information:

ANGIODYNAMICS, Inc. intends to introduce the following device into commercial distribution:

a) Trade Name: AngioDynamics, Inc. DuraMaxTM

Hemodialysis Catheter and Procedure

b) **Common Name:** Long Term Hemodialysis Catheter

c) **Classification Name:** Hemodialysis Catheter, Implanted

d) Manufacturing Site Address: ANGIODYNAMICS, Inc. 603 Queensbury Avenue Queensbury, New York

12804

e) **Manufacturing Establishment**

Registration Number:

1319211

f) **Sterilization Site Address:** Sterigenics

84 Park Rd.

Glens Falls, NY 12801

g) Sterilizer Establishment Registration Number

13196189

h) Classification: Hemodialysis Catheter, Implanted

Product Code: 78 MSD 21 CFR 876.5540

Device Class: Class III

i) Device Equivalence:

This product is substantially equivalent to the following devices:

- Ash Access Ash Advance Hemodialysis Catheter and Procedure Kit, K070572
- MedComp Hemo-Flow Double Lumen Catheter, K994105, 24 40 cm lengths
- MedComp Hemo-Flow Double Lumen Catheter 55 cm, K030502, 55 cm in length for femoral placement

This device does not present additional risks to patients or different considerations regarding safety and effectiveness than those presented by the predicate devices.

j) Performance Standards:

None Established

k) AngioDynamics® Contact Information:

Name:

Teri Juckett, Regulatory Affairs Manager

Address:

603 Queensbury Avenue

Queensbury, New York 12804

Phone:

(518) 798-1215 extension 1142

Fax:

(518) 798-3625

Email:

tjuckett@angiodynamics.com

l) Payment Identification Number: MD6033959-956733



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

MAY 13 2008

Ms. Teri Juckett Regulatory Affairs Manager ANGIODYNAMICS, Inc. 603 Queensbury Avenue OUEENSBURY NY 12804

Re: K080400

Trade/Device Name: AngioDynamics, Inc. DuraMax[™] Hemodialysis Catheter and

Procedure Kit

Regulation Number: 21 CFR §876.5540

Regulation Name: Blood access device and accessories

Regulatory Class: III Product Code: MSD Dated: February 12, 2008 Received: February 13, 2008

Dear Ms. Juckett:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act). You may, therefore, market the device, subject to the general controls provisions of Act. However, you are responsible to determine that the medical devices you use as components in the kit have either been determined as substantially equivalent under the premarket notification process (Section 510(k) of the act), or were on the market prior to May 28, 1976, the enactment date of the Medical Device Amendments. *Please note:* If you purchase your device components in bulk (i.e., unfinished) and further process (e.g., sterilize) you must submit a new 510(k) before including these components in your kit. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation, please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll free number (800) 638-2041 or (240) 276-3150, or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Nancy C. Brogdon

Director, Division of Reproductive, Abdominal,

and Radiological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

INDICATIONS FOR USE

510(k) Application: New Application **Device Name:** AngioDynamics, Inc. DuraMaxTM Hemodialysis Catheter and Procedure Kit Indications for Use: The AngioDynamics, Inc. DuraMaxTM Hemodialysis Catheter is indicated for use in attaining long-term vascular access for hemodialysis and apheresis. It may be inserted percutaneously and is primarily placed in the internal jugular vein of an adult patient. Alternative insertion sites include the subclavian vein as required. Catheters greater than 40cm are intended for femoral vein insertion. This catheter is indicated for > 30 days long-term placement. Prescription Use ___ OR Over-the-Counter Use (Per 21 CFR 801.109) Please do not write below this line - continue on another page if needed Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign-Off) Division of Reproductive, Abdominal and Radiological Devices 510(k) Number